FDA Takes Up Bid to Expand Gazyva for Lupus After New Phase 3 Trial
The FDA has accepted a filing to expand Gazyva for systemic lupus erythematosus, but the IV drug is not approved for broader lupus in the U.S. yet.
Clinical Trials
Trial launches, interim results, approvals, safety signals, and what they may mean for patients.
-
-
A widely used arthritis drug did not help inflammatory knee osteoarthritis in a recent trial
A randomized trial found methotrexate did not meaningfully improve inflammatory knee osteoarthritis, underscoring that proven knee OA care still matters most.
-
New Trial Suggests Team-Based Care and Home Monitoring Can Improve Blood Pressure Control in Lower-Income Adults
A randomized trial in community health centers found that team-based support plus home blood pressure checks improved systolic pressure more than enhanced usual care.
-
FDA Cleared a New Once-Daily Psoriasis Pill. What That Means for People With Moderate to Severe Plaque Psoriasis
FDA approved Icotyde on March 17, 2026, giving some adults and teens with moderate to severe plaque psoriasis a new once-daily pill option.
-
FDA Approved a New Daily Obesity Pill: What the Orforglipron Trials Found and What They Still Can’t Tell Us
The FDA approved daily obesity pill orforglipron on April 1. Here is what its main placebo-controlled trial found, and what patients still do not know.
-
Brain | Clinical Trials | Dementia | Elderly
A Short Brain-Training Program Was Linked to Fewer Dementia Diagnoses Over 20 Years. What Older Adults Should Know
An NIH-backed 20-year follow-up links one specific speed-training program—not all brain games—to fewer dementia diagnoses. Here’s what it means.
-
New Blood Thinner Study May Change Conversations After a Dangerous Clot
A new trial found less clinically important bleeding with apixaban than rivaroxaban after a serious clot, but treatment changes still need a clinician.
-
Before You Stop a Statin or Ask for the New Cholesterol Pill: How to Read a Medical-Study Headline
Two February 2026 cholesterol headlines show how to judge study design, real outcomes, and official guidance before changing a medicine or screening plan.
-
Can Rheumatoid Arthritis Be Delayed? What a New Abatacept Study Really Found
A January 2026 follow-up study suggests one year of abatacept may delay rheumatoid arthritis in a narrowly defined high-risk group, but it did not prove permanent prevention or create a new plan for everyday joint aches.
-
NIH Wants Clinical Trial Volunteers to Get Plain-Language Results. What That Could Mean for Patients
NIH says it is developing a policy framework that could make plain-language study-result summaries more routine for people in NIH-funded clinical research. Here’s what that could mean, what is still only proposed, and what patients should ask before joining a trial.
-
New JAMA Trial: Spinal Manipulation Alone Did Not Beat Usual Medical Care for Acute Low Back Pain
A large new randomized trial found that spinal manipulation by itself did not significantly outperform guideline-based medical care for pain or disability over 1 year in adults with acute or subacute low back pain at higher risk of long-term problems. Here’s what that means for chiropractic care, self-management, and when back pain needs prompt medical evaluation.
-
A New Migraine Prevention Option for Some Kids: What the Latest Ajovy Study Means for Families
A newly published New England Journal of Medicine trial adds stronger evidence behind Ajovy for some children and teens with episodic migraine. The study found modest average benefit, not a cure, and the current U.S. label applies only to patients ages 6 to 17 who weigh 45 kg or more.
-
A New Oral Gonorrhea Drug Won FDA Approval. What the Zoliflodacin Trial Actually Found
The FDA has approved Nuzolvence, an oral form of zoliflodacin, for some uncomplicated gonorrhea cases. Here is what the phase 3 trial found, what noninferior means, and why this does not apply to every gonorrhea infection.
-
Thinking About Chiropractic for Low Back Pain? What the Newest Evidence Says
A new NCCIH consumer update and a large recent JAMA trial point in the same direction: spinal manipulation may help some people with low back pain, but average benefits are usually small, and it works best as one part of a broader plan built around movement, exercise, and self-management.
-
FDA’s New Bone-Density Shortcut for Osteoporosis Drug Trials: What It Means, and What It Doesn’t
The FDA’s December 19, 2025 decision could make some osteoporosis drug trials smaller and faster. But it does not change who should get screened, how osteoporosis is diagnosed, or what most patients should do today.
-
GLP-1 Weight-Loss Drugs and Heart Disease: What the Latest Evidence Means for Patients in 2026
A large randomized trial found that semaglutide reduced heart attacks and strokes in adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Here’s what the evidence shows, what the FDA approval means, and what U.S. patients should know about safety, cost, and coverage.
End of content
End of content
